{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:33:58Z","timestamp":1787668438898,"version":"build-2736575974"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13256-018-1849-y","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T12:08:46Z","timestamp":1538654926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature"],"prefix":"10.1186","volume":"12","author":[{"given":"P","family":"Ramachandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Morcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Onukogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Spinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen C","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"1849_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S-I, Watanabe H, Kurashina K, Hatanaka H. Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561.","journal-title":"Nature"},{"key":"1849_CR2","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bmc.2011.12.021","volume":"20","author":"K Kinoshita","year":"2012","unstructured":"Kinoshita K, Asoh K, Furuichi N, Ito T, Kawada H, Hara S, Ohwada J, Miyagi T, Kobayashi T, Takanashi K, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem. 2012;20:1271\u201380.","journal-title":"Bioorg Med Chem"},{"key":"1849_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, Ou S-HI, P\u00e9rol M, Dziadziuszko R, Rosell R. Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer. N Engl J Med. 2017;377:829\u201338.","journal-title":"N Engl J Med"},{"key":"1849_CR4","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1016\/S1470-2045(17)30482-5","volume":"18","author":"JA Gilbert","year":"2017","unstructured":"Gilbert JA. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC. Lancet Oncol. 2017;18:e377. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30482-5\n                    \n                  .","journal-title":"Lancet Oncol"},{"key":"1849_CR5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","volume":"14","author":"T Seto","year":"2013","unstructured":"Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1\u20132 study. The Lancet Oncology. 2013;14:590\u20138.","journal-title":"The Lancet Oncology"},{"key":"1849_CR6","first-page":"65","volume":"3","author":"PN Tran","year":"2016","unstructured":"Tran PN, Klempner SJ. Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. Front Med (Lausanne). 2016;3:65.","journal-title":"Front Med (Lausanne)"},{"key":"1849_CR7","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jtho.2017.06.070","volume":"12","author":"JC Yang","year":"2017","unstructured":"Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, et al. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12:1552\u201360.","journal-title":"J Thorac Oncol"},{"key":"1849_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","volume":"15","author":"SM Gadgeel","year":"2014","unstructured":"Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study. Lancet Oncol. 2014;15:1119\u201328.","journal-title":"Lancet Oncol"},{"key":"1849_CR9","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.2147\/OTT.S136837","volume":"10","author":"M Shimada","year":"2017","unstructured":"Shimada M, Fukuda M, Fukuda M, Kitazaki T, Hashiguchi K, Ikeda T, Yamaguchi H, Nakatomi K, Ashizawa K, Mukae H. Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction. Onco Targets Ther. 2017;10:3211\u20134.","journal-title":"Onco Targets Ther"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1849-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-018-1849-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1849-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T23:23:58Z","timestamp":1571441038000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-018-1849-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1849"],"URL":"https:\/\/doi.org\/10.1186\/s13256-018-1849-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"15 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"303"}}